SHY-ONC6 / SHY Therapeutics - LARVOL DELTA

SHY Therapeutics…announced that the first patient has been dosed in Luca-1, the Company's first-in-human Phase 1 clinical trial evaluating SHY-ONC6, an investigational, novel and potentially first-in-class oral proteasome inhibitor for patients with advanced solid tumors (GlobeNewswire) - "The Company expects initial Phase 1 data in 2027....The Luca-1 trial is a first-in-human, open-label, multicenter Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of SHY-ONC6 in patients with advanced solid tumors."

First-in-human • P1 data • Trial status • Colon Cancer • Gastric Cancer • Hepatocellular Cancer • Hormone Receptor Positive Breast Cancer • Mesothelioma • Non Small Cell Lung Cancer • Pancreatic Cancer • Prostate Cancer • Soft Tissue Sarcoma • Triple Negative Breast Cancer

Luca-1: A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: SHY Therapeutics

First-in-human • New P1 trial • Breast Cancer • Castration-Resistant Prostate Cancer • Colon Cancer • Colorectal Cancer • Gastric Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer